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OBJECTIVES We sought to determine the efficacy of calcium antagonists (CAs) in reducing death,
myocardial infarction (MI), ischemia, and supraventricular tachyarrhythmia (SVT) after
cardiac surgery.
BACKGROUND Calcium antagonists may reduce complications after cardiac surgery—namely, death, MI, and
renal failure. However, they are underused, possibly due to the results from previous
observational studies.
METHODS Both MEDLINE (1966 to December 2001) and EMBASE (1980 to December 2001) were
searched, with supplementation by reference list searches. No language restrictions were
applied. Included studies were randomized, controlled trials (RCTs) evaluating preoperative,
intraoperative, or postoperative (first 48 h) CA use (intravenous or oral) during aortocoronary
bypass or valve surgery. Studies were excluded if they exclusively recruited transplant
recipients, individuals 18 years old, or patients with pre-existing SVT. Two reviewers
independently evaluated study quality by using the Jadad score; a minimal score of 1/5 was
required. Forty-one studies, encompassing 3,327 patients, were included. No studies assessed
treatment exclusively with short-acting oral nifedipine. Treatment effects were calculated
using the random-effects model. Heterogeneity was assessed using the Q test.
RESULTS Calcium antagonists significantly reduced MI (odds ratio [OR] 0.58, 95% confidence interval
[CI] 0.37 to 0.91; p  0.02) and ischemia (OR 0.53, 95% CI 0.39 to 0.72; p  0.001).
Non-dihydropyridines significantly reduced SVT (OR 0.62, 95% CI 0.41 to 0.93; p  0.02).
Calcium antagonists were associated with trends toward decreased mortality during aorto-
coronary bypass (OR 0.66, 95% CI 0.26 to 1.70, p  0.4).
CONCLUSIONS Use of CAs during cardiac surgery significantly reduced rates of MI, ischemia, and SVT.
Further study using large RCTs is justified. (J Am Coll Cardiol 2003;41:1496–505)
© 2003 by the American College of Cardiology Foundation
Coronary artery bypass graft surgery (CABG), the most
common cardiac surgical procedure (1), reduces morbidity
(2) and mortality (3) from coronary artery disease. However,
cardiac surgery remains associated with significant compli-
cations, including death, myocardial infarction (MI), neu-
rocognitive dysfunction, and acute renal failure. Strategies that
reduce these events should therefore improve overall outcomes.
See page 1506
Calcium antagonists (CAs) may reduce these complica-
tions. They improve balance between myocardial oxygen
supply and demand through negative chronotropic, negative
inotropic, afterload-reducing, and coronary vasodilatory
properties. An imbalance between myocardial oxygen sup-
ply and demand causes ischemia, thereby potentially leading
to MI (4). Calcium antagonist–mediated vasodilation may
reduce post-CABG graft spasm, another cause of postop-
erative ischemia (5). Calcium antagonists prevent supraven-
tricular tachyarrhythmias (SVTs) (6), therefore potentially
reducing postoperative atrial fibrillation, which is associated
with neurocognitive dysfunction (7) and prolonged hospi-
talization (8). Also, CAs may limit renal damage by de-
creasing renal vascular resistance and increasing the glomer-
ular filtration rate (9). These benefits vary by CA class:
benzothiazepines (e.g., diltiazem), phenylalkylamines (e.g., ve-
rapamil), and dihydropyridines (e.g., nifedipine, amlodipine).
Despite these benefits, CAs are underused (10). The
reasons for this are unclear, although there are at least three
possibilities: CAs have shown no perioperative benefit in
previous observational studies (10–12). Second, CAs’ neg-
ative inotropic properties may have led to concerns regard-
ing exacerbating left ventricular dysfunction. Third, short-
acting oral nifedipine, a dihydropyridine, has been associated
with increased mortality in non-surgical studies (13).
Given this discrepancy between theoretical benefits and
clinical practice, a systematic review of randomized, con-
trolled trials (RCTs) evaluating CAs during cardiac surgery
is justified.
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METHODS
This review was conducted according to the Quality of
Reports of Meta-Analyses of Randomized Controlled Tri-
als (QUOROM) recommendations (14).
Inclusion and exclusion criteria. Eligible studies were
published RCTs that evaluated CAs (administered imme-
diately preoperatively, intraoperatively, or postoperatively
within 48 h) during CABG or valve surgery and reported
any of the following outcomes: death, MI, ischemia, SVT,
or creatinine clearance. Perioperative outcomes were defined
as occurring between the initiation of surgery and postop-
erative day 30. Ischemia was defined as ST-segment devi-
ation on the electrocardiogram or new wall motion abnor-
malities on the transesophageal echocardiogram. The SVTs
included atrial fibrillation, atrial flutter, and supraventricular
tachycardia. We did not strictly define MI, given the lack of
uniform criteria in the literature. Studies were ineligible if
they exclusively recruited organ transplant recipients, indi-
viduals18 years old, or individuals with pre-existing SVT.
Studies were also ineligible if CAs were exclusively admin-
istered as a cardioplegic additive.
Search strategy, methodologic assessment, and data ab-
straction. We identified RCTs by searching MEDLINE
(1966 to December 2001) [calcium channel blockers AND
(postoperative complications OR perioperative care OR
intraoperative complications)] and EMBASE (1980 to
December 2001) [calcium channel blocking agent AND
(postoperative complication OR postoperative period OR
peroperative period OR intraoperative period OR peropera-
tive care OR peroperative complication)], without language
restriction. Titles and abstracts were screened to exclude
ineligible studies. Two reviewers (Drs. Wijeysundera and
Beattie) independently read the remaining studies and rated
their quality using the Jadad score (15). This validated
five-point scale assesses RCT quality based on the adequacy
of randomization, blinding, and follow-up. The minimal
score required was 1. Bibliographies of included studies
were surveyed.
The following were abstracted independently by two
reviewers (Drs. Wijeysundera and Beattie) onto standard-
ized forms: patients, surgery, treatments, death, MI, isch-
emia, SVT, creatinine clearance, previous medications, low
cardiac output syndrome, inotropic support, pacing, and
blood loss. We did not strictly define low cardiac output
syndrome, given the heterogeneity of definitions in the
literature. Inotropic support was defined as the need for
inotropes or intra-aortic balloon pump support. Where
possible, we abstracted data only for comparisons of CAs
against placebo or nitroglycerin. All disagreements were
resolved by consensus.
Primary analyses. Treatment effects for dichotomous out-
comes were expressed as odds ratios (ORs), with 95%
confidence intervals (CIs). Treatment effects on continuous
outcomes were expressed as weighted mean differences. We
employed the random-effects model and Q test to calculate
pooled treatment effects and heterogeneity, respectively. All
calculations were performed using Review Manager version
4.1 (Cochrane Collaboration, Oxford, U.K.). Statistical
significance for treatment effects and heterogeneity were
defined by p values 0.05 and 0.1, respectively.
The effects of CAs on death, MI, ischemia, SVT, and
postoperative creatinine clearance were calculated. We de-
termined CAs’ effects on several adverse events: low cardiac
output syndrome, inotropic support, pacing, and blood loss.
We also compared previous beta-blocker and CA use
between the CA and non-CA arms, given that differences in
medication use may have affected estimates of treatment
effects. We employed the fixed-effects model for compari-
sons of adverse events and previous medication use.
Secondary analyses. Subgroup analyses were performed for
each CA class (diltiazem, verapamil, dihydropyridines). We
also compared CAs specifically against nitroglycerin, which
has been considered a superior prophylaxis against post-
CABG ischemia (16). Calcium antagonists may differen-
tially impact patients with coronary artery disease; therefore,
we performed a subgroup analysis for patients who under-
went CABG alone.
Sensitivity analyses. We performed several sensitivity
analyses to determine the robustness of our findings. We
repeated the meta-analyses after successively withdrawing
trials with the most favorable CA treatment effects. To
assess the effect of study quality on estimates of treatment
effect, we repeated the meta-analyses in subgroups of trials
with Jadad scores 0, 1, and 2. Funnel plots were
performed to assess for a publication bias.
RESULTS
Forty-one studies, encompassing 3,327 patients, were in-
cluded (17–57) (Table 1). The search results are presented
in Figure 1. The median Jadad score was 1 (range 1 to 4). A
single study assessed concurrent CA treatment given sys-
temically and as a cardioplegic additive (44); it was the only
study that assessed short-acting oral nifedipine. A list of
excluded studies is available from the authors.
Mortality and cardiovascular outcomes. Eleven studies
reported deaths, with an incidence among 1,001 patients of
3.1%. The CAs did not affect mortality (OR 1.01; p  1)
(Fig. 2), without significant heterogeneity (chi-squared
statistic  7.99; p  0.63). A nimodipine study (47) found
that it significantly increased mortality, largely due to
excessive bleeding. When nimodipine studies (43,47) were
Abbreviations and Acronyms
CA  calcium antagonist
CABG  coronary artery bypass graft surgery
MI  myocardial infarction
RCT  randomized, controlled trial
SVT  supraventricular tachyarrhythmia
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excluded, the OR for mortality was 0.66 (95% CI 0.26 to
1.70; p  0.4).
Twenty-two trials reported MIs, with an incidence
among 1,853 patients of 4.7%. The CAs significantly
reduced MI (OR 0.58, 95% CI 0.37 to 0.91; p 0.02) (Fig.
3), without significant heterogeneity (chi-square  7.56;
p  1). Subgroup analyses suggested that diltiazem (OR
0.55, 95% CI 0.26 to 1.20; p  0.13) and dihydropyridines
(OR 0.46, 95% CI 0.22 to 0.96; p  0.04) reduced MI to
a greater degree than did verapamil (OR 0.83, 95% CI 0.35
to 1.98; p  0.7). The definition of perioperative MI varied
between studies. A post hoc analysis of studies strictly
defining MI, a priori, as significant new Q waves and/or
elevated creatine kinase, MB fraction (5% or 50 U/l)
(18,21,23,25,28,31–33,41,46,52–54) showed an improved
reduction in perioperative MI (OR 0.49, 95% CI 0.28 to
0.86; p  0.01).
Twenty studies reported ischemia, with an incidence
Table 1. Included Trials
Authors (ref.) CA Arm Control Arm Treatment Duration n
Jadad
Score
CABG
Amano et al. 1995 (17) Diltiazem (0.12 mg/kg per h IV) Control Intraop to 1 day postop 23 1
Apostolidou et al. 1999 (37) Nicardipine (0.7–1.4 g/kg per min IV) Nitroglycerin (0.5–1 g/kg per min IV),
control
1 day postop 77 2
Babin-Ebell et al. 1996 (18) Diltiazem (0.1 mg/kg per h IV) Control Intraop to 3 days postop 70 2
Bertolissi et al. 1996 (38) Nifedipine (0.24–0.59 g/kg per min IV) Control Intraop 20 2
Colson et al. 1992 (19) Diltiazem (0.12 mg/kg per h IV) Placebo Intraop 29 3
Combes et al. 1992 (39) Nicardipine (2–4 mg/h IV) Nitroprusside (0.5–2 g/kg per min IV) 1 day postop 16 1
David et al. 1991 (40) Nicardipine (2–4 mg/h IV) Nitroprusside (0.5–6 g/kg per min IV) 1 day postop 74 1
Davison et al. 1985 (20) Verapamil (80 mg 4/day orally) Placebo 1–7 days postop 200 4
Donegani et al. 1986 (21) Diltiazem (0.03–0.12 mg/kg per h IV) Control Intraop to 2 days postop 40 1
Donmez et al. 1998 (56) Nimodipine (1–15 g/kg per h IV) Dopamine (2 g/kg per min IV) Intraop 50 1
Dupuis et al. 1992 (41) Nifedipine (0.2 g/kg per min IV) Control 4 h postop 63 3
Ferraris et al. 1987 (22) Verapamil (80 mg 3/day orally) Placebo 7 days postop 113 4
Hannes et al. 1993 (23) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to 1 day postop 91 1
Hannes et al. 1995 (24) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to 1 day postop 64 2
Hicks et al. 1984 (44) Nifedipine (10 mg 4/day sublingually)* Control Postop 39 1
Himle et al. 2000 (25) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 mg/h IV) 5 days preop to 1 day
postop
49 1
Keilich et al. 1997 (26) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to postop until
discharge
211 2
Knothe et al. 1993 (45) Nifedipine (0.25 g/kg per min IV) Nitroglycerin (1.5 g/kg per min IV),
control
Intraop 45 1
Koolen et al. 1989 (46) Nicardipine (5 g/kg per min IV) Placebo Intraop 56 1
Lassnigg et al. 2001 (27) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to 1 day postop 49 4
Leslie et al. 1994 (48) Isradipine (8.3–16.6 g/min IV) Nitroprusside (25–50 g/min IV) 1 day postop 178 3
Lischke et al. 1995 (28) Diltiazem (0.12 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop 55 1
Malhotra et al. 1997 (29) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to 1 day postop 71 2
Nathan et al. 1992 (49) Nifedipine (0.67–1 g/kg per min IV) Nitroprusside (0.5–8 g/kg per min IV) 1 day postop 49 2
Petry et al. 1992 (50) Nifedipine (0.5 g/kg per min IV) Nitroglycerin (3 g/kg per min IV) Intraop 44 1
Ruegg et al. 1992 (51) Isradipine (0.075–0.3 g/kg per min IV) Nitroprusside (0.5 g/kg per min IV) 3 h postop 198 3
Seitelberger et al. 1994 (31) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to 1 day postop 120 1
Seitelberger et al. 1991 (53) Nifedipine (10 g/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to 1 day postop 104 2
Seitelberger et al. 1990 (52) Nifedipine (10 g/kg per h IV) Nitroglycerin (1 g/kg per min IV) 1 day postop 50 2
Shapira et al. 2000 (32) Diltiazem (0.1 mg/kg per h IV) Nitroglycerin (1 g/kg per min IV) Intraop to discharge 161 1
Smith et al. 1985 (33) Verapamil (40 mg 3/day orally) Control 1–8 days postop 91 2
van Wezel et al. 1989(a) (54) Nicardipine (3 g/kg per min IV) Nitroprusside (1 g/kg per min IV) Intraop 90 1
van Wezel et al. 1989(b) (55) Nicardipine (3 g/kg per min IV) Control Intraop 80 1
van Wezel et al. 1986 (57) Verapamil (0.6 mg/kg per h IV),
nifedipine (0.7 g/kg per min IV)
Nitroglycerin (0.7 g/kg per min IV),
control
Intraop 80 1
Williams et al. 1985 (35) Verapamil (80 mg 3/day orally) Placebo 1–5 days postop 141 4
Zanardo et al. 1993 (36) Diltiazem (0.12 mg/kg per h IV) Control Intraop to 1 day postop 23 1
Valve surgery
Legault et al. 1996 (47) Nimodipine (30 mg 4/day orally) Placebo 1–5 days postop 149 4
Tschirkov et al. 1992 (34) Diltiazem (60 mg 3/day orally) Control 5 days preop to intraop 72 1
Mixed
Fang et al. 1995 (42) Nicardipine (20 mg 3/day orally) Control 7 days preop 21 1
Forsman et al. 1990 (43) Nimodipine (0.5 g/kg per min IV) Placebo Intraop 35 3
Schoneberger et al. 1992 (30) Verapamil (3 mg/h IV) Control Postop until discharge 136 1
*Verapamil 1 mg/l was added to the cardioplegia solution in the calcium antagonist arm only.
CA  calcium antagonist; CABG  coronary artery bypass graft surgery; IV  intravenously.
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among 1,522 patients of 17.1%. The CAs significantly
reduced ischemia (OR 0.53, 95% CI 0.39 to 0.72; p 
0.001) (Fig. 4), without significant heterogeneity (chi-
square  16.62; p  0.62). Subgroup analyses showed that
diltiazem (OR 0.60, 95% CI 0.35 to 1.05; p  0.07) and
dihydropyridines (OR 0.47, 95% CI 0.32 to 0.71; p 
0.001) reduced perioperative ischemia.
Fifteen studies reported SVT, with an incidence of 17.3%
among 1,756 patients. Overall, the CAs’ effect on periop-
erative SVT was non-significant (OR 0.73, 95% CI 0.48 to
1.12; p  0.15) (Fig. 5). The Q test, however, indicated
significant heterogeneity among these studies. Subgroup
analyses suggested that dihydropyridines and non-
dihydropyridines had opposite effects on SVT (Fig. 4).
Non-dihydropyridines significantly reduced SVT (OR 0.62,
95% CI 0.41 to 0.93; p  0.02), whereas dihydropyridines
non-significantly increased SVT (OR 2.69, 95% CI 0.57 to
12.64). When considered individually, diltiazem (OR 0.54,
95% CI 0.28 to 1.04) and verapamil (OR 0.69, 95% CI 0.42
to 1.15) similarly reduced SVT.
The effects of CAs on mortality, MI, ischemia, or SVT
were not qualitatively affected by temporal trends, indica-
tions for CA treatment (ischemia, hypertension, SVT), or
exclusion of the study that concurrently administered CAs
orally with a cardioplegic solution (44).
Renal function. Five studies (17,36,38,50,56), encompass-
ing 161 patients, reported creatinine clearance. The CAs
Figure 1. Meta-analysis flow diagram. CCB  calcium channel blocker;
RCT  randomized controlled trial.
Figure 2. Effects on mortality. CCB  calcium channel blocker; CI  confidence interval; df  degrees of freedom; OR  odds ratio.
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non-significantly increased postoperative creatinine clear-
ance (7.65 ml/min increase; 95% CI 4.21 to 19.51
ml/min; p  0.2). However, there was significant hetero-
geneity (chi-square  19.63; p  0.0006).
We performed post hoc analyses to explain this hetero-
geneity. The CAs significantly improved postoperative cre-
atinine clearance if preoperative creatinine clearance was
95 ml/min (13.12 ml/min increase; 95% CI 9.16 to 17.07;
p  0.001), without significant heterogeneity (chi-square 
1.30; p  0.52). The CAs also non-significantly worsened
postoperative renal function if preoperative creatinine clear-
ance was 95 ml/min (5.03 ml/min decrease; 95% CI
12.38 to 2.33; p  0.18), without significant heterogene-
ity (chi-square  0.20; p  0.66). Subgroup analyses based
on CA class did not remove the statistical heterogeneity
within each subgroup.
Figure 3. Effects on myocardial infarction. Abbreviations as in Figure 2.
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Secondary analyses. Compared with nitroglycerin, CAs
reduced MI (OR 0.51, 95% CI 0.25 to 1.06; p  0.07),
ischemia (OR 0.65, 95% CI 0.39 to 1.09; p  0.10), and
SVT (OR 0.52, 95% CI 0.26 to 1.14; p  0.10). There was
no significant heterogeneity for the effects on MI (chi-
square 2.23; p 0.95) and ischemia (chi-square 10.48;
p  0.23); however, there was significant heterogeneity for
effects on SVT (chi-square 14.62; p 0.012). Relative to
nitroglycerin, CAs had no effect on mortality (OR 1.18,
95% CI 0.37 to 3.79; p  0.8).
Among patients who underwent CABG, CAs reduced
mortality (OR 0.66, 95% CI 0.26 to 1.70; p 0.4), MI (OR
0.58, 95% CI 0.37 to 0.91; p  0.02), ischemia (OR 0.53,
95% CI 0.39 to 0.73; p  0.001), and SVT (OR 0.76, 95%
CI 0.48 to 1.21; p  0.3). There was no significant
heterogeneity for effects on mortality (chi-square  3.17;
p  0.92), MI (chi-square  7.56; p  1), and ischemia
(chi-square  16.17; p  0.58); however, there was signif-
icant heterogeneity for effects on SVT (chi-square  31.07;
p  0.0033).
Previous medication use. Nineteen trials reported previ-
ous beta-blocker use (18,19,23,24,26 –28,31,33,36 –
38,41,46,49,51,54,55,57). Patients in the CA arm of these
trials were significantly less likely to have been on beta-
blockers preoperatively (OR 0.76, 95% CI 0.60 to 0.96; p
0.02), without significant heterogeneity (chi-square  8.36;
p  0.94). Eighteen trials reported previous CA use
(18,19,23,24,26 –28,31,33,36 –38,41,46,49,54,55,57). Pa-
tients assigned to the CA arm were non-significantly less
likely to have been on CAs preoperatively (OR 0.81, 95%
Figure 4. Effects on ischemia. Abbreviations as in Figure 2.
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CI 0.64 to 1.03; p  0.08), without significant heterogene-
ity (chi-square  9.41; p  0.90).
Adverse events. Three studies reported low cardiac output
syndrome (19,32,34). There was no difference between the
CA and non-CA arms (OR 1.01, 95% CI 0.25 to 4.11; p
1), without significant heterogeneity (chi-square  2.28;
p  0.32). Eleven trials reported inotropic support
(18,19,21,27,31,32,34,36,41,49,57). There was no differ-
ence between the CA and non-CA arms (OR 0.98, 95% CI
0.62 to 1.53; p  0.9), without significant heterogeneity
(chi-square  13.73; p  0.19). Three trials reported
postoperative pacing (32,34,57). The CAs were associated
with a significant increase in pacing (OR 6.57, 95% CI 3.54
to 12.18; p  0.001), without significant heterogeneity
(chi-square  0.50; p  0.78).
Three studies reported postoperative blood loss
(29,39,40). The difference between the CA and non-CA
arms was non-significant (difference 0.47 ml; p  1),
without significant heterogeneity (chi-square  1.70; p 
0.43). A nimodipine trial (47) found that significant bleed-
ing, as defined by requirement of 10 U blood during the
operative period or chest drainage of 2,400 ml within
24 h, was increased in the CA arm (OR 3.64; p  0.04).
Sensitivity analyses. The effect on MI became non-
significant when the four trials with the smallest ORs (i.e.,
most favorable CA treatment effects) were excluded. Ex-
cluding the nine most favorable trials resulted in a non-
significant effect on ischemia. Excluding the two most
favorable trials removed non-dihydropyridines’ significant
effect on SVT. The effects of CAs on MI, ischemia, and
SVT were not affected by study quality (Table 2). Funnel
plots for mortality and MI revealed no obvious publication
bias.
DISCUSSION
To our knowledge, this is the first systematic review in the
literature to examine CA use during cardiac surgery. Over-
all, CAs decreased perioperative MI and ischemia; in
subgroup analyses, diltiazem and verapamil decreased peri-
Figure 5. Effects on supraventricular tachyarrhythmia. Abbreviations as in Figure 2.
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operative SVT. This meta-analysis followed current guide-
lines (14). The literature search was extensive, encompass-
ing all languages. We employed the conservative random-
effects model to calculate treatment effects. These estimates
remained significant even when 20% to 45% of the most
favorable studies were removed.
The CAs significantly reduced MI, an important clinical
benefit for cardiac surgical patients. Perioperative MI is
associated with increased in-hospital mortality (58). Its
effects on long-term survival are more controversial; how-
ever, it is associated with decreased three-year survival
among individuals with previous MI or ventricular dysfunc-
tion (58). We did not apply a strict definition of MI, given
the heterogeneity in the literature. This is unlikely to have
affected our results. Patients were directly compared only
within the same study. Furthermore, in a post hoc analysis,
the treatment effect was improved when analyses were
restricted to trials employing common definitions of MI.
The CAs significantly reduced perioperative ischemia.
Both intraoperative (4) and postoperative (59) myocardial
ischemia have been associated with an increased risk of MI.
Diltiazem and verapamil significantly reduced SVT.
Overall, the CAs are unlikely to significantly affect SVT,
given the varying chronotropic properties of CA classes.
Perioperative SVT reduction is clinically important. Post-
operative atrial fibrillation is associated with worsened
postoperative outcomes (7,8).
The CAs significantly increased postoperative creatinine
clearance among individuals with decreased preoperative
renal function. The renal-protective properties of CAs are
likely to vary with preoperative renal function. However,
these findings reflect a post hoc analysis of 200 patients.
Nonetheless, these results justify further study among pa-
tients with pre-existing renal insufficiency.
The CAs did not affect overall mortality. However, the
analysis was greatly affected by the negative study of Legault
et al. (47), who found that perioperative nimodipine signif-
icantly increased mortality, largely due to increased postop-
erative bleeding. These patients all underwent hypothermic
cardiopulmonary bypass, however. Hypothermia impairs
platelet activity (60), reduces coagulation factor function
(61), and increases perioperative blood loss (62). Further-
more, only 46% received aminocaproic acid, an antifibrino-
lytic agent that reduces blood loss during cardiac surgery by
30% to 40% (63). The mortality benefit of CAs may apply
specifically to patients undergoing CABG. In this subgroup,
CAs non-significantly reduced mortality.
The effects of CAs on bleeding warrant further discus-
sion. The present analysis lacks sufficient power to examine
CAs’ overall and class-specific effects on perioperative
bleeding, because only three included studies reported the
outcome. In vitro, dihydropyridines (64), verapamil (65),
and diltiazem (66) all reduce platelet aggregation. However,
these in vitro effects are unlikely to have clinically signifi-
cance. An abstract, referred to in a review of CAs’ adverse
effects (67), found no increased risk of bleeding among
5,157 cardiac surgical patients. However, this 1996 abstract
has not been subsequently published in full. The same
review (67) concluded that most of the clinical data linking
CAs and bleeding point against an increased risk.
The CAs did not increase the incidence of low cardiac
output syndrome or inotropic support. Although postoper-
ative pacing was increased, there were no associated adverse
hemodynamic effects. These benign chronotropic and ino-
tropic effects are in contrast to CA cardioplegic additives,
which were associated with increased inotropic support (68)
and prolonged electromechanical arrest (69).
Our results should be interpreted cautiously. The quality
of included studies affects the magnitude of pooled treat-
ment effects (70). The majority of included trials were
unblinded. However, we did conduct sensitivity analyses to
examine the effect of poorer study quality on our results.
The treatment effects on MI and ischemia were essentially
unchanged when lower quality studies were excluded.
Blinding was not employed during study evaluation and
data abstraction. This did not significantly affect our results
(71,72). As with all meta-analyses, our review may have
been affected by a publication bias. Our analyses did include
trials where CAs had neutral or negative effects, however.
Language restrictions were not applied, therefore removing
that component of publication bias. Unpublished data were
excluded; however, the importance of this in meta-analyses
is still debatable (73).
There certainly was clinical heterogeneity among the
studies with regard to patient characteristics, drug dose, and
duration of therapy. However, we employed statistical tests
that indicated that most pooled treatment effects were
unaffected by heterogeneity. Furthermore, p values for these
tests were consistently 0.60 for overall analyses pertaining
to mortality, MI, and ischemia.
Therefore, our results justify evaluating perioperative
Table 2. Sensitivity Analyses Based on Quality of Randomized, Controlled Trial
Jadad
Score
OR for MI
(95% CI)
Patients in
Trials Reporting
MI (n)
OR for Ischemia
(95% CI)
Patients in
Trials Reporting
Ischemia (n)
OR for SVT*
(95% CI)
Patients in
Trials Reporting
SVT* (n)
1 0.58 (0.37–0.91) 1,853 0.53 (0.39–0.72) 1,522 0.62 (0.41–0.93) 1,465
2 0.52 (0.29–0.93) 1,014 0.50 (0.33–0.77) 932 0.66 (0.43–1.02) 957
3 0.55 (0.23–1.35) 480 0.45 (0.25–0.81) 517 0.65 (0.37–1.14) 450
*Nondihydropyridine studies only.
CI  confidence interval; MI  myocardial infarction; OR  odds ratio; SVT  supraventricular tachyarrhythmia.
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CAs in a large, simple, double-blinded RCT, the best
method of estimating CAs’ true efficacy. We suggest that
this trial should evaluate CAs among patients undergoing
CABG, the subgroup most likely to benefit from CAs.
Conclusions. Our meta-analysis indicated that CA use
during cardiac surgery significantly reduced perioperative
MI and ischemia. Furthermore, non-dihydropyridines sig-
nificantly reduced perioperative SVT. Further study is
needed to determine the true effects of CAs on the afore-
mentioned outcomes, as well as their effect on perioperative
mortality.
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